Researchers use exosome-based strategy to block HIV in mice nih.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nih.gov Daily Mail and Mail on Sunday newspapers.
South African variant yet more concerning
Study on AstraZeneca vaccine’s efficacy against B.1.351 shows “disappointing” results.
Geoff Caddick / AFP / Getty Images
Early in February, the South African government suspended the AstraZeneca vaccine rollout after a small-scale trial found that the vaccine’s efficacy against the coronavirus variant (B.1.351) first identified in South Africa was highly reduced.
Now, a new study, published today in
NEJM, found that the AstraZeneca vaccine might offer as little as 10% protection from developing mild to moderate COVID-19 infection caused by the South African variant.
Scientists conducted a double-blind, placebo-controlled trial across multiple hospitals in South Africa to assess the AstraZeneca vaccine’s efficacy. Participants were randomly divided into two groups and administered two doses of either the vaccine or placebo.
Pregnant women, the elderly still unknowns in coronavirus vaccine rollout
By medical reporter Sophie Scott and the Specialist Reporting Team s Nick Sas
Posted
MonMonday 25
updated
TueTuesday 26
JanJanuary 2021 at 1:58am
The World Health Organization does not recommend the COVID-19 vaccines for pregnant women due to insufficient data .
(
Print text only insufficient evidence to recommend routine use of COVID-19 vaccines during pregnancy.
It comes as the Australian Government says there are some things we don t yet know about the COVID-19 vaccines including their potential impact on pregnant women and the elderly but maintains very careful clinical decisions will be made about at-risk groups.